IGC Pharma Secures New Patent for Treatment Method, Expanding Therapeutic Offerings

IGC Pharma has been granted a patent for a method to treat stuttering, stammering, and Tourette's syndrome using THC and/or CBD. The biotechnology company is focused on developing cannabinoid-based treatments for various diseases and conditions, including Alzheimer's disease. IGC Pharma's financial health is mixed, with a negative operating margin and net margin, but a relatively low debt-to-equity ratio. The company's revenue growth has been promising over a three-year period, and it has secured a patent for its new treatment method.

IGC Pharma, Inc. (NYSE American: IGC) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909, which covers a novel treatment method using THC and/or CBD for stammering, stuttering, and Tourette's syndrome. This patent, known as IGC510, represents a significant milestone in the company's intellectual property portfolio.

The patent application, which combines low doses of atypical antipsychotics with low doses of THC, is designed to target the endocannabinoid system. This approach aims to improve treatment effectiveness in Tourette's syndrome, stuttering, and stammering while reducing the side effects typically associated with high-dose THC or antipsychotic treatments. Globally, an estimated 75 million people are affected by these conditions, highlighting the potential market size for this new treatment.

IGC Pharma's Chief Executive Officer, Ram Mukunda, commented, "Securing this NOA adds to our growing IP portfolio, which includes patents for Alzheimer's, pain, and eating disorders. We plan to move the research to clinical formulations similar to IGC-AD1, our flagship medication that also contains low doses of THC and is in the CALMA Phase 2 clinical trials." By focusing on microdoses, IGC510 has the potential to address a critical unmet need for patients suffering from stammering, stuttering, and Tourette's syndrome with a safer therapeutic profile.

About IGC Pharma
IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Its lead asset, IGC-AD1, is a cannabinoid-based therapy currently in Phase 2 trials (CALMA) for agitation in Alzheimer's dementia. The company's pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. With more than 30 active patent filings and 12 granted patents, IGC Pharma is committed to innovation and advancing breakthrough therapies.

Financial Overview
IGC Pharma's financial health is mixed, with a negative operating margin and net margin over the past three years. However, the company has demonstrated promising revenue growth, and the patent allowance for IGC510 could potentially open up new revenue streams. The company's debt-to-equity ratio remains relatively low, indicating a manageable financial position.

Forward-Looking Statements
This press release contains forward-looking statements, which are based on IGC Pharma's expectations and subject to several risks and uncertainties. Actual results could differ materially from these forward-looking statements as a result of various factors, including the company's ability to commercialize its products, regulatory approvals, and general economic conditions.

References:
[1] https://www.morningstar.com/news/accesswire/1066474msn/igc-pharma-receives-notice-of-allowance-for-novel-thc-microdose-based-treatment-for-stammering-stuttering-and-tourettes-syndrome
[2] https://www.stocktitan.net/news/IGC/igc-pharma-receives-notice-of-allowance-for-novel-thc-microdose-4s1lunvm2myw.html